{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:35:09Z","timestamp":1792550109902,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T00:00:00Z","timestamp":1708387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1007\/s00259-024-06635-8","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T08:02:26Z","timestamp":1708416146000},"page":"1981-1988","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["[68Ga]Ga-FAP-2286, a novel promising theragnostic approach for PET\/CT imaging in patients with various type of metastatic cancers"],"prefix":"10.1007","volume":"51","author":[{"given":"Seyedeh Somayyeh","family":"Banihashemian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghasemali","family":"Divband","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elahe","family":"Pirayesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babak","family":"Nikkholgh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamidreza","family":"Amini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdolghafar Abolhosseini","family":"Shahrnoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Nami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9938-3587","authenticated-orcid":false,"given":"Mohammad Esmaeil","family":"Akbari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,20]]},"reference":[{"key":"6635_CR1","doi-asserted-by":"publisher","first-page":"758958","DOI":"10.3389\/fonc.2021.758958","volume":"11","author":"S Kuyumcu","year":"2021","unstructured":"Kuyumcu S, Sanli Y, Subramaniam RM. Fibroblast-activated protein inhibitor PET\/CT: cancer diagnosis and management. Front Oncol. 2021;11:758958.","journal-title":"Front Oncol"},{"key":"6635_CR2","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3390\/biomedicines10030523","volume":"10","author":"L Gilardi","year":"2022","unstructured":"Gilardi L, Air\u00f2 Farulla LS, Demirci E, Clerici I, Omodeo Sal\u00e8 E, Ceci F. Imaging cancer-associated fibroblasts (CAFs) with FAPi PET. Biomedicines. 2022;10:523.","journal-title":"Biomedicines"},{"key":"6635_CR3","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2967\/jnumed.120.244806","volume":"62","author":"A Altmann","year":"2021","unstructured":"Altmann A, Haberkorn U, Siveke J. The latest developments in imaging of fibroblast activation protein. J Nucl Med. 2021;62:160\u20137.","journal-title":"J Nucl Med"},{"issue":"Pt 3","key":"6635_CR4","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.semcancer.2022.04.008","volume":"86","author":"A Peltier","year":"2022","unstructured":"Peltier A, Seban R-D, Buvat I, Bidard F-C, Mechta-Grigoriou F. Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging. Semin Cancer Biol. 2022;86(Pt 3):262\u201372.","journal-title":"Semin Cancer Biol"},{"key":"6635_CR5","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/imr.12978","volume":"302","author":"R Mhaidly","year":"2021","unstructured":"Mhaidly R, Mechta-Grigoriou F. Role of cancer-associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer. Immunol Rev. 2021;302:259\u201372.","journal-title":"Immunol Rev"},{"key":"6635_CR6","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1084\/jem.20122344","volume":"210","author":"EW Roberts","year":"2013","unstructured":"Roberts EW, Deonarine A, Jones JO, Denton AE, Feig C, Lyons SK, et al. Depletion of stromal cells expressing fibroblast activation protein-\u03b1 from skeletal muscle and bone marrow results in cachexia and anemia. J Exp Med. 2013;210:1137\u201351.","journal-title":"J Exp Med"},{"key":"6635_CR7","doi-asserted-by":"crossref","unstructured":"Tran E, Chinnasamy D, Yu Z, Morgan RA, Lee C-CR, Restifo NP, Rosenberg SA. Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia. J Exp Med. 2013;210:1125\u201335.","DOI":"10.1084\/jem.20130110"},{"key":"6635_CR8","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.3390\/ph14101023","volume":"14","author":"S Imlimthan","year":"2021","unstructured":"Imlimthan S, Moon ES, Rathke H, Afshar-Oromieh A, R\u00f6sch F, Rominger A, Gourni E. New frontiers in cancer imaging and therapy based on radiolabeled fibroblast activation protein inhibitors: a rational review and current progress. Pharmaceuticals. 2021;14:1023.","journal-title":"Pharmaceuticals"},{"key":"6635_CR9","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.2967\/jnumed.118.210435","volume":"59","author":"A Loktev","year":"2018","unstructured":"Loktev A, Lindner T, Mier W, Debus J, Altmann A, J\u00e4ger D, et al. A tumor-imaging method targeting cancer-associated fibroblasts. J Nucl Med. 2018;59:1423\u20139.","journal-title":"J Nucl Med"},{"key":"6635_CR10","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.2967\/jnumed.118.210443","volume":"59","author":"T Lindner","year":"2018","unstructured":"Lindner T, Loktev A, Altmann A, Giesel F, Kratochwil C, Debus J, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein. J Nucl Med. 2018;59:1415\u201322.","journal-title":"J Nucl Med"},{"key":"6635_CR11","doi-asserted-by":"publisher","first-page":"e194003","DOI":"10.1148\/rycan.2019194003","volume":"1","author":"DK Hathi","year":"2019","unstructured":"Hathi DK, Jones EF. 68Ga FAPI PET\/CT: tracer uptake in 28 different kinds of cancer. Radiol Imaging Cancer. 2019;1:e194003.","journal-title":"Radiol Imaging Cancer"},{"key":"6635_CR12","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","volume":"60","author":"C Kratochwil","year":"2019","unstructured":"Kratochwil C, Flechsig P, Lindner T, Abderrahim L, Altmann A, Mier W, et al. 68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer. J Nucl Med. 2019;60:801\u20135.","journal-title":"J Nucl Med"},{"key":"6635_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41181-019-0069-0","volume":"4","author":"T Lindner","year":"2019","unstructured":"Lindner T, Loktev A, Giesel F, Kratochwil C, Altmann A, Haberkorn U. Targeting of activated fibroblasts for imaging and therapy. EJNMMI Radiopharm Chem. 2019;4:1\u201315.","journal-title":"EJNMMI Radiopharm Chem"},{"key":"6635_CR14","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","volume":"60","author":"A Loktev","year":"2019","unstructured":"Loktev A, Lindner T, Burger E-M, Altmann A, Giesel F, Kratochwil C, et al. Development of fibroblast activation protein\u2013targeted radiotracers with improved tumor retention. J Nucl Med. 2019;60:1421\u20139.","journal-title":"J Nucl Med"},{"key":"6635_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2967\/jnumed.120.258467","volume":"63","author":"C Qin","year":"2022","unstructured":"Qin C, Shao F, Gai Y, Liu Q, Ruan W, Liu F, et al. 68Ga-DOTA-FAPI-04 PET\/MR in the evaluation of gastric carcinomas: comparison with 18F-FDG PET\/CT. J Nucl Med. 2022;63:81\u20138.","journal-title":"J Nucl Med"},{"key":"6635_CR16","doi-asserted-by":"publisher","first-page":"4396","DOI":"10.1007\/s00259-021-05475-0","volume":"48","author":"M Sollini","year":"2021","unstructured":"Sollini M, Kirienko M, Gelardi F, Fiz F, Gozzi N, Chiti A. State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2021;48:4396\u2013414.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6635_CR17","doi-asserted-by":"publisher","first-page":"693640","DOI":"10.3389\/fonc.2021.693640","volume":"11","author":"H Wang","year":"2021","unstructured":"Wang H, Zhu W, Ren S, Kong Y, Huang Q, Zhao J. Ga-FAPI-04 versus (18) F-FDG PET\/CT in the detection of hepatocellular carcinoma. Front Oncol. 2021;11:693640.","journal-title":"Front Oncol"},{"key":"6635_CR18","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.122.264544","volume":"64","author":"Y Pang","year":"2023","unstructured":"Pang Y, Zhao L, Meng T, Xu W, Lin Q, Wu H, et al. PET imaging of fibroblast activation protein in various types of cancer using (68)Ga-FAP-2286: comparison with (18)F-FDG and (68)Ga-FAPI-46 in a single-center, prospective study. J Nucl Med. 2023;64:386\u201394. https:\/\/doi.org\/10.2967\/jnumed.122.264544.","journal-title":"J Nucl Med"},{"key":"6635_CR19","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2967\/jnumed.119.236786","volume":"61","author":"C Meyer","year":"2020","unstructured":"Meyer C, Dahlbom M, Lindner T, Vauclin S, Mona C, Slavik R, et al. Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients. J Nucl Med. 2020;61:1171\u20137.","journal-title":"J Nucl Med"},{"issue":"10","key":"6635_CR20","doi-asserted-by":"publisher","first-page":"3221","DOI":"10.1007\/s00259-021-05266-7","volume":"48","author":"J Ferdinandus","year":"2021","unstructured":"Ferdinandus J, Kessler L, Hirmas N, Trajkovic-Arsic M, Hamacher R, Umutlu L, et al. Equivalent tumor detection for early and late FAPI-46 PET acquisition. Eur J Nuclear Med Mol Imaging. 2021;48(10):3221\u20137.","journal-title":"Eur J Nuclear Med Mol Imaging"},{"key":"6635_CR21","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.3390\/jcm10061267","volume":"10","author":"B Camus","year":"2021","unstructured":"Camus B, Cottereau A-S, Palmieri L-J, Dermine S, Tenenbaum F, Brezault C, Coriat R. Indications of peptide receptor radionuclide therapy (PRRT) in gastroenteropancreatic and pulmonary neuroendocrine tumors: an updated review. J Clin Med. 2021;10:1267.","journal-title":"J Clin Med"},{"key":"6635_CR22","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","volume":"49","author":"D Zboralski","year":"2022","unstructured":"Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E, et al. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur J Nucl Med Mol Imaging. 2022;49:3651\u201367.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6635_CR23","doi-asserted-by":"publisher","first-page":"415","DOI":"10.2967\/jnumed.120.259192","volume":"63","author":"RP Baum","year":"2022","unstructured":"Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, Zhang J, et al. Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using 177Lu-FAP-2286: first-in-humans results. J Nucl Med. 2022;63:415\u201323.","journal-title":"J Nucl Med"},{"issue":"6","key":"6635_CR24","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1007\/s00259-021-05591-x","volume":"49","author":"P Zhang","year":"2022","unstructured":"Zhang P, Xu M, Ding J, Chen J, Zhang T, Huo L, Liu Z. Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy. Eur J Nucl Med Mol Imaging. 2022;49(6):1985\u201396.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6635_CR25","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1007\/s00259-020-04769-z","volume":"47","author":"H Chen","year":"2020","unstructured":"Chen H, Pang Y, Wu J, Zhao L, Hao B, Wu J, et al. Comparison of [68 Ga] Ga-DOTA-FAPI-04 and [18 F] FDG PET\/CT for the diagnosis of primary and metastatic lesions in patients with various types of cancer. Eur J Nucl Med Mol Imaging. 2020;47:1820\u201332.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6635_CR26","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.122.264544","volume":"64","author":"Y Pang","year":"2023","unstructured":"Pang Y, Zhao L, Meng T, Xu W, Lin Q, Wu H, et al. PET imaging of fibroblast activation protein in various types of cancer using 68Ga-FAP-2286: comparison with 18F-FDG and 68Ga-FAPI-46 in a single-center, prospective study. J Nucl Med. 2023;64:386\u201394.","journal-title":"J Nucl Med"},{"key":"6635_CR27","doi-asserted-by":"publisher","first-page":"7235","DOI":"10.1073\/pnas.87.18.7235","volume":"87","author":"P Garin-Chesa","year":"1990","unstructured":"Garin-Chesa P, Old LJ, Rettig WJ. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc Natl Acad Sci. 1990;87:7235\u20139.","journal-title":"Proc Natl Acad Sci"},{"key":"6635_CR28","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1038\/s41388-018-0275-3","volume":"37","author":"E Pur\u00e9","year":"2018","unstructured":"Pur\u00e9 E, Blomberg R. Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene. 2018;37:4343\u201357.","journal-title":"Oncogene"},{"key":"6635_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1479-5876-11-187","volume":"11","author":"PC Schuberth","year":"2013","unstructured":"Schuberth PC, Hagedorn C, Jensen SM, Gulati P, van den Broek M, Mischo A, et al. Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells. J Transl Med. 2013;11:1\u201311.","journal-title":"J Transl Med"},{"key":"6635_CR30","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1097\/rlu.0000000000003810","volume":"46","author":"M Assadi","year":"2021","unstructured":"Assadi M, Rekabpour SJ, Jafari E, Divband G, Nikkholgh B, Amini H, et al. Feasibility and therapeutic potential of 177Lu\u2013fibroblast activation protein inhibitor\u201346 for patients with relapsed or refractory cancers: a preliminary study. Clin Nucl Med. 2021;46:e523\u201330. https:\/\/doi.org\/10.1097\/rlu.0000000000003810.","journal-title":"Clin Nucl Med"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06635-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06635-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06635-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,30]],"date-time":"2024-05-30T10:05:42Z","timestamp":1717063542000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06635-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,20]]},"references-count":30,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["6635"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06635-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,20]]},"assertion":[{"value":"6 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This prospective study was approved by the Research Ethics Committee of Shahid Beheshti University of Medical Sciences in Tehran, Iran (IR.SBMU.CRC.REC.1402.040), and a written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients participating in the present study and the authors consent to publish and print the information contained in this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}